ELAN vs. BNTX, ONC, TEVA, SMMT, ITCI, GMAB, RDY, VTRS, MRNA, and ASND
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health vs.
BioNTech (NASDAQ:BNTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
BioNTech has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
BioNTech presently has a consensus target price of $141.73, indicating a potential upside of 43.63%. Elanco Animal Health has a consensus target price of $15.17, indicating a potential upside of 19.77%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts plainly believe BioNTech is more favorable than Elanco Animal Health.
Elanco Animal Health has a net margin of 4.60% compared to BioNTech's net margin of -15.16%. Elanco Animal Health's return on equity of 6.78% beat BioNTech's return on equity.
BioNTech received 5 more outperform votes than Elanco Animal Health when rated by MarketBeat users. However, 54.96% of users gave Elanco Animal Health an outperform vote while only 47.45% of users gave BioNTech an outperform vote.
15.5% of BioNTech shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, BioNTech had 5 more articles in the media than Elanco Animal Health. MarketBeat recorded 21 mentions for BioNTech and 16 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.43 beat BioNTech's score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the news media.
BioNTech has higher earnings, but lower revenue than Elanco Animal Health. BioNTech is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Elanco Animal Health beats BioNTech on 10 of the 19 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
This page (NYSE:ELAN) was last updated on 5/24/2025 by MarketBeat.com Staff
Buy ELAN Stock Free ELAN Stock Alerts